Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLATFORM2 in Patients With Advanced Solid Tumors
NCT07307053Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jan 2026
- Primary completion
- Jan 2029
- Modality
- CAR-T Cells, Antibody-Drug Conjugates (ADCs), Fc-Fusion Proteins
01
Overview
A Phase 2 trial of izalontamab brengitecan, vesicular stomatitis virus, CVL006, IDOV-Safe, YL201, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
izalontamab brengitecanvesicular stomatitis virusCVL006IDOV-SafeYL201
Beyond the preview
Go deeper on NCT07307053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07307053.